{
    "nctId": "NCT00869206",
    "briefTitle": "Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",
    "officialTitle": "A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone, Pain, Musculoskeletal Complication, Urinary Complications",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 1822,
    "primaryOutcomeMeasure": "Percentage of Participants With at Least One Skeletal-related Event (SRE) Within 2 Years After Randomization",
    "eligibilityCriteria": "Eligibility Criteria:\n\n* Histologic documentation of one of the following: breast adenocarcinoma, prostate adenocarcinoma or multiple myeloma\n* At least one site of bone metastasis or bone involvement by radiologic imaging including plain radiograph, computed tomography (CT), positron emission tomography (PET) scan, PET/CT scan, magnetic resonance imaging, bone scan, or skeletal survey; indeterminate lesions should be confirmed by a second imaging method\n* No prior treatment with IV bisphosphonates is allowed; prior treatment with oral bisphosphonates is allowed, but they must be discontinued prior to the initiation of protocol therapy\n* No prior treatment with denosumab\n* No prior treatment with radiopharmaceuticals; prior treatment with radioactive iodine is allowed; prostate cancer patients treated with brachytherapy are eligible\n* Prior radiation therapy to bone is allowed, provided that at least one site of bone metastasis has not been irradiated and radiation is completed prior to registration; there should be no plan for radiation therapy to non-irradiated sites of bone metastases\n* Prior adjuvant and metastatic chemotherapy, biologic therapy, and endocrine therapy is allowed\n* No current treatment with investigational agent(s)\n* Patients with known brain metastases are not eligible; patients who develop brain metastases during the study will be allowed to continue treatment as assigned\n* Not pregnant and not nursing\n* ECOG performance status 0-2\n* Calculated creatinine clearance \\>= 30 mL/min\n* Corrected serum calcium \\>= 8.0 mg/dL (2.00 mmol/L) and \\< 11.6 mg/dL (2.90 mmol/L) \\* Corrected serum calcium should be calculated using standard institutional practices",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}